Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Mark Levine Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Immunovant

Mark has more than 25 years of legal experience, including negotiating mergers, acquisitions, and divestitures; managing licensing agreements and partnerships; and providing counsel to optimize development and commercialization. Mark most recently served as General Counsel and Corporate Secretary of Flexion Therapeutics, Inc., a commercial stage biopharmaceutical company, where he was a member of the executive committee and was responsible for overseeing all legal and compliance affairs related to Flexion’s launch of ZILRETTA® in the United States in 2017 and building its pipeline. Mark’s tenure at Flexion culminated in the acquisition of the company by Pacira BioSciences, Inc. in late 2021. Mark previously served as General Counsel and Corporate Secretary at Minerva Neurosciences, Inc.

Mark holds a B.A. from Binghamton University, SUNY, and a J.D. from Washington University School of Law in St. Louis.

What is Mark S. Levine's net worth?: The estimated net worth of Mark S. Levine is at least $8.20 million as of February 22nd, 2024. Mr. Levine owns 301,968 shares of Immunovant stock worth more than $8,204,471 as of April 27th. This net worth estimate does not reflect any other investments that Mr. Levine may own. Learn More about Mark S. Levine's net worth.
How old is Mark S. Levine?: Mr. Levine is currently 51 years old. There are 6 older executives and no younger executives at Immunovant. The oldest executive at Immunovant is Dr. William L. Macias M.D., Ph.D., Chief Medical Officer, who is 66 years old. Learn More on Mark S. Levine's age.
How do I contact Mark S. Levine?: The corporate mailing address for Mr. Levine and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Mark S. Levine's contact information.
Has Mark S. Levine been buying or selling shares of Immunovant?: Mark S. Levine has not been actively trading shares of Immunovant during the last ninety days. Most recently, Mark S. Levine sold 2,134 shares of the business's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $36.15, for a transaction totalling $77,144.10. Following the completion of the sale, the insider now directly owns 301,968 shares of the company's stock, valued at $10,916,143.20. Learn More on Mark S. Levine's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 1,526,316 shares worth more than $58,000,008.00. During the last twelve months, insiders at the sold shares 33 times. They sold a total of 432,966 shares worth more than $10,713,116.07. The most recent insider tranaction occured on April, 24th when insider Michael Geffner sold 3,261 shares worth more than $94,242.90. Insiders at Immunovant own 4.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 4/24/2024.

Mark S. Levine Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2024	Sell	2,134	$36.15	$77,144.10	301,968
1/26/2024	Sell	3,027	$37.92	$114,783.84	304,102
10/25/2023	Sell	4,107	$34.66	$142,348.62	310,381
8/24/2023	Sell	12,286	$20.30	$249,405.80	314,488
7/26/2023	Sell	3,917	$21.63	$84,724.71	326,774
1/26/2023	Sell	10,156	$18.51	$187,987.56	245,660

Mark S. Levine Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $27.17

$26.97

$27.97

50 Day Range

MA: $32.10

$27.17

$38.36

2 Week Range

Now: $27.17

$15.90

$45.58

Volume

1,414,961 shs

Average Volume

1,003,272 shs

Market Capitalization

$3.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Protect Yourself While There’s Still Time …

From Weiss Ratings | Ad